The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Clearing Glaucoma's Cellular Clutter
Glaucoma Neuro-ophthalmology News

Clearing Glaucoma's Cellular Clutter

Pharmacologically restoring mitochondrial clearance for impaired autophagy could offer new neuroprotection route

11/17/2026 2 min read

Share

  • Full Article
  • Summary
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
Objective:

To investigate whether impaired autophagy and mitophagy contribute to mitochondrial accumulation, oxidative stress, and retinal ganglion cell (RGC) degeneration in glaucoma.

Approach:
  • Models: Researchers used glucocorticoid-induced and myocilin-associated mouse glaucoma models, mitophagy reporter mice, RGC-specific genetic manipulation, and ex vivo human retinal tissue.
  • Interventions and measures: They assessed mitochondrial structure, mitophagy, oxidative damage, RGC function and survival, and optic nerve axons; they also tested autophagy activation with intravitreal Torin 2.
Key Findings:
  • Sustained ocular hypertension was associated with abnormal mitochondrial accumulation and oxidative DNA damage in RGCs and optic nerve axons.
  • Mitophagy was reduced after five weeks of ocular hypertension, before detectable RGC loss and axonal degeneration, and remained impaired after degeneration was established.
  • RGC-specific disruption of Atg5 was followed by mitochondrial abnormalities, oxidative DNA damage, impaired RGC function, approximately 39% RGC loss, and approximately 59% loss of healthy optic nerve axons.
  • In the glucocorticoid-induced mouse model, Torin 2 increased mitophagy and preserved RGC function without changing IOP. Mean pattern electroretinography amplitudes were 31.82 µV in treated hypertensive eyes versus 17.36 µV in control-treated eyes; treatment was also associated with 37% more RGCs and 51% more morphologically intact axons.
  • In neurotrophic factor-deprived human retinal explants, Torin 2 increased RGC survival by approximately 49.7%.
Interpretation:

The authors’ findings place impaired mitochondrial clearance before detectable RGC degeneration in the studied models and support further investigation of autophagy and mitophagy as potential neuroprotective targets.

Limitations:
  • The work is preclinical.
  • In the myocilin model, some neuroprotection may have resulted from an accompanying reduction in IOP.
  • Torin 2 broadly inhibits mTOR, which may complicate translation; the authors propose studying more selective autophagy or mitophagy modulators.
Conclusion:

The authors state that future studies will focus on selective autophagy/mitophagy modulators or pathway-specific interventions to validate and refine mitophagy-targeted approaches for glaucoma.

Sources:
  • Article context; study published in Molecular Neurodegeneration

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: